# Effectiveness and Safety of Lidocaine-Nifedipine Combination in Patients With Acute and Chronic Anal Fissure: A Retrospective, Multi-centric, Post-marketing Surveillance Study

**Authors:** G Santhi Vardhani, R S Arun, Paramjeet Singh Sandhu, Rajan Madan, M Shenthil Prabhu, Snehal Purandare, Tarun Agarwal, Anjana Yadav, Sanjay Kamble

PMC · DOI: 10.7759/cureus.103680 · Cureus · 2026-02-15

## TL;DR

This study found that a cream combining lidocaine and nifedipine effectively heals anal fissures and reduces pain and bleeding, with minimal side effects.

## Contribution

The study provides new evidence on the effectiveness and safety of a lidocaine-nifedipine combination for treating anal fissures in both acute and chronic cases.

## Key findings

- The combination cream significantly resolved anal fissures and reduced pain and bleeding over eight weeks.
- Acute fissure patients showed greater improvement in bleeding reduction and pain relief compared to chronic cases.
- All reported adverse events were mild and self-limiting, indicating good tolerability.

## Abstract

Background

Anal fissures (AFs) are common and painful conditions that are frequently managed surgically; however, they are limited by fecal incontinence. Pharmacological management with calcium channel blockers has recently gained acceptance. This study aimed to evaluate the effectiveness and safety of twice-daily nifedipine (0.3% w/w) and lidocaine (1.5% w/w) cream in patients with acute AF (AAF) and chronic AF (CAF).

Methods

This retrospective, multi-centric, post-marketing surveillance study was conducted over a period of four weeks in the Department of Gastroenterology and Surgery across 46 institutes. The study included data of 431 patients with AAF (n=290) and CAF (n=141). The primary outcome measure was the percentage of patients with healed AFs, assessed at Weeks 1, 4, and 8. The secondary outcome measures were pain relief, evaluated using a 5-point VAS; percentage of patients with bleeding per anus; and adverse events (AEs), assessed at baseline and weekly follow-up intervals for eight weeks.

Results

At eight weeks, AF resolved significantly compared to the baseline (p<0.0001). During similar intervals, the incidence of bleeding per anus decreased significantly (p<0.0001), coupled with a significant reduction in the VAS score (p<0.0001). Though the resolution of AFs was comparable between AAF and CAF (p>0.05), the patients with AAF had a significantly greater reduction in bleeding per anus at Weeks 7 and 8 (p<0.05), with a significant decrease in the VAS score at Week 8 (p<0.05). All reported AEs were mild and self-limiting.

Conclusion

Topical nifedipine-lidocaine resulted in significant AF resolution, with significant pain relief and reduction in bleeding per anus, together with excellent tolerability.

## Linked entities

- **Chemicals:** Lidocaine (PubChem CID 3676), Nifedipine (PubChem CID 4485)

## Full-text entities

- **Diseases:** bleeding (MESH:D006470), AFs (MESH:D005401), fecal incontinence (MESH:D005242), AAF (MESH:D000208), pain (MESH:D010146), CAF (MESH:D002908)
- **Chemicals:** Lidocaine (MESH:D008012), Nifedipine (MESH:D009543)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12996345/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC12996345/full.md

---
Source: https://tomesphere.com/paper/PMC12996345